Evidence map›Paper›PMID 32790155›Full record

ArticleAnnals of clinical and translational neurology2020

Elevated matrix metalloproteinase-9 levels in neuronal extracellular vesicles in Alzheimer's disease.

Dongmei Gu, Fang Liu, Meng Meng, Liling Zhang, Marc L Gordon, Ying Wang, Li Cai, Nan Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of clinical and translational neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 6 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 6 syntheses or guidelines pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Dongmei GuDepartment of Clinical Laboratory, Tianjin Medical University General Hospital, Tianjin, China.
Fang LiuDepartment of Neurology, Tianjin Medical University General Hospital, Tianjin, China.
Meng MengDepartment of Neurology, Tianjin Medical University General Hospital Airport Hospital, Tianjin, China.
Liling ZhangDepartment of Neurology, Heji Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, China.
Marc L GordonThe Litwin-Zucker Research Center, The Feinstein Institutes for Medical Research, Northwell Health, 350 Community Drive, Manhasset, New York.
Ying WangDepartment of PET-CT Diagnostic, Tianjin Medical University General Hospital, Tianjin, China.
Li CaiDepartment of PET-CT Diagnostic, Tianjin Medical University General Hospital, Tianjin, China.
Nan ZhangDepartment of Neurology, Tianjin Medical University General Hospital, Tianjin, China.ORCID 0000-0002-9675-5322
Tianjin Medical University General Hospital · CNChangzhi Medical College · CNNorthwell Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aimed to investigate plasma neuronally derived extracellular vesicle (NDEV) levels of core pathological markers [amyloid-β (Aβ) and phosphorylated tau] and inflammatory biomarkers, including interleukin 6 (IL-6) and matrix metalloproteinase-9 (MMP-9) in patients with Alzheimer's disease (AD).

methodsThirty-one patients with AD and 15 cognitively normal controls (NCs) were recruited. The diagnosis of AD was supported by fluorodeoxyglucose and Pittsburgh Compound-B PET scans. Plasma extracellular vesicles were extracted, precipitated, and enriched for neuronal source by anti-L1CAM antibody absorption. Levels of Aβ42, P-T181-tau, P-S396-tau, IL-6, and MMP-9 in plasma NDEVs were quantified by enzyme-linked immunosorbent assay (ELISA).

resultsAβ42, P-T181-tau, and MMP-9 levels in plasma NDEVs were significantly higher in patients with AD than NCs. However, P-S396-tau and IL-6 levels in plasma NDEVs did not differ between AD patients and NCs. Moreover, there was no correlation between any of these biomarker levels and cognitive function as measured with Mini-Mental State Examination in patients with AD.

conclusionsThese findings provide further support that levels of core pathological markers, including Aβ42 and P-T181-tau, are elevated in plasma NDEVs of patients with AD. Furthermore, MMP-9 might play an important role in the pathogenesis of AD, and is a promising inflammatory biomarker for AD.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseAmyloid beta-PeptidesBiomarkersExtracellular VesiclesFemaleHumansInterleukin-6MaleMatrix Metalloproteinase 9Middle AgedNeuronsPeptide Fragmentstau ProteinsAmyloid beta-Peptidesamyloid beta-protein (1-42)BiomarkersIL6 protein, humanInterleukin-6MAPT protein, humanMatrix Metalloproteinase 9MMP9 protein, humanPeptide Fragmentstau Proteins

Identifiers

PMID32790155
PMCPMC7480907
OpenAlexW3048654501

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.